[Effectiveness of Strontium-89 for Neuropathic Pain Caused by Bone Metastases from Breast Cancer: A Case Report].

Y. Iizuka, M. Iizuka-Ohashi, S. Kawasaki, Ichiro Nakai, T. Mizowaki
{"title":"[Effectiveness of Strontium-89 for Neuropathic Pain Caused by Bone Metastases from Breast Cancer: A Case Report].","authors":"Y. Iizuka, M. Iizuka-Ohashi, S. Kawasaki, Ichiro Nakai, T. Mizowaki","doi":"10.18893/kakuigaku.cr.1901","DOIUrl":null,"url":null,"abstract":"The patient was a 47-year-old female with stage IV breast cancer and multiple bone metastases. She received various systemic therapies (hormone therapy and chemotherapy) and underwent mastectomy between 2013 and 2018; in the beginning of 2018, she started experiencing bone metastatic pain in the right hip joint and neural pain on the dorsal side of the left thigh. These symptoms worsened gradually, and nonsteroidal anti-inflammatory analgesics or narcotic analgesics were not effective for treating this pain. Strontium-89 (89Sr) treatment was administered in April 2018. The pain was relieved immediately after 89Sr treatment. The patient's quality of life improved markedly. She spent her remaining life without using analgesic drugs, until she died in October 2018 due to exacerbation of the original disease. Although radiotherapy is believed to be less effective for neuropathic pain than for bone metastatic pain, it should be considered as a treatment option in patients with neuropathic pain.","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kaku igaku. The Japanese journal of nuclear medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18893/kakuigaku.cr.1901","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The patient was a 47-year-old female with stage IV breast cancer and multiple bone metastases. She received various systemic therapies (hormone therapy and chemotherapy) and underwent mastectomy between 2013 and 2018; in the beginning of 2018, she started experiencing bone metastatic pain in the right hip joint and neural pain on the dorsal side of the left thigh. These symptoms worsened gradually, and nonsteroidal anti-inflammatory analgesics or narcotic analgesics were not effective for treating this pain. Strontium-89 (89Sr) treatment was administered in April 2018. The pain was relieved immediately after 89Sr treatment. The patient's quality of life improved markedly. She spent her remaining life without using analgesic drugs, until she died in October 2018 due to exacerbation of the original disease. Although radiotherapy is believed to be less effective for neuropathic pain than for bone metastatic pain, it should be considered as a treatment option in patients with neuropathic pain.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[锶-89治疗乳腺癌骨转移性神经性疼痛1例报告]。
患者是一名47岁的女性,患有IV期乳腺癌和多发性骨转移。2013年至2018年,她接受了各种全身治疗(激素治疗和化疗),并接受了乳房切除术;2018年初,她开始出现右髋关节骨转移性疼痛和左大腿背侧神经疼痛。这些症状逐渐加重,非甾体类抗炎镇痛药或麻醉性镇痛药对治疗这种疼痛无效。2018年4月进行锶-89 (89Sr)治疗。经89Sr治疗后疼痛立即缓解。病人的生活质量明显改善。直到2018年10月,由于原发疾病恶化,她在没有使用止痛药的情况下度过了余生。尽管人们认为放射治疗对神经性疼痛的效果不如骨转移性疼痛,但它应该被视为神经性疼痛患者的一种治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊介绍: The main scope of JSNM is the appropriate development of the application of radioactive substances and stable nuclides in medicine. Towards this scope, JSNM promotes the exchange of idea and information, and researches in nuclear medicine. JSNM are interested in the international collaboration for the development of nuclear medicine. Through the activities, JSNM contributes to the medicine, as well as humanity, not only in Japan but also in any countries over the world.
期刊最新文献
[The 44th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 47th Survey in 2021)].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1